Society guideline links: Waldenström macroglobulinemia

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Monoclonal gammopathy of undetermined significance".)

International

●Consensus Panel 1 (CP1) from the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11): Report on management of symptomatic, treatment-naïve patients (2023)

●Consensus Panel 2 (CP2) from the IWWM-11: Report on the management of relapsed or refractory WM patients (2023)

●Consensus Panel 3 (CP3) from the IWWM-11: Report on recommendations for molecular diagnosis in Waldenström's macroglobulinemia (2023)

●Consensus Panel 4 (CP4) from the IWWM-11: Report on diagnostic and response criteria (2023)

●Consensus Panel 6 (CP6) from the IWWM-11: Report on management of Waldenström's macroglobulinemia related amyloidosis (2023)

●IWWM: Consensus panel recommendations for the investigation and management of IgM and Waldenström-associated peripheral neuropathies (2017)

Europe

●European Myeloma Network (EMN): Recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018)

●European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment and follow-up of Waldenström's macroglobulinaemia (2018)

United Kingdom

●British Society for Haematology (BSH): Guidelines on the diagnosis and management of Waldenström macroglobulinaemia (2022)

Australia–New Zealand

●Myeloma Australia Medical and Scientific Advisory Group (MSAG): Clinical practice update for treatment of patients with Waldenström macroglobulinaemia (2023)

•Myeloma Australia Medical and Scientific Advisory Group (MSAG): Consensus clinical practice (2022)

●Myeloma Australia MSAG, Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), and Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG): A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia – Recommendations (2020)

Japan

●[In Japanese] Japanese Society of Hematology (JSH): Clinical practice guidelines for hematological malignancies, 2nd edition (2020)